Despite Narrow Miss on EPS, Stoke Therapeutics Advances in Clinical Developments
Stoke Therapeutics ( NASDAQ:STOK ) First Quarter 2024 Results Key Financial Results Net loss: US$26.4m (loss widened by...
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 5% and 26.61%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?